Will Viking Therapeutics be acquired before 2027?

Prediction markets put the probability at 58%: Will Viking Therapeutics be acquired before 2027. Currently, markets are divided (58% YES, 42% NO). Subscribe from just £3.65 a week and unlock full access to exclusive interviews, rights deals, industry data and more:.

What’s Happening

Speculation around whether Viking Therapeutics will be acquired before 2027 intensified through early May 2026 as large-cap pharma earnings reset M&A appetite. Vertex Pharmaceuticals confirmed CFO Charlie Wagner will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on May 19, 2026, with CEO Reshma Kewalramani following at Bernstein's 42nd Annual Strategic Decisions Conference on May 29, 2026 — venues historically used by Big Pharma to telegraph capital deployment plans. Vertex carries roughly $11.2 billion in cash and equivalents, sufficient firepower for a mid-cap obesity asset like Viking, whose VK2735 dual GLP-1/GIP program remains the single most-cited rumored target in sell-side notes. [BioSpace, May 12]

Comparable biotech transactions frame the upside math. When Pfizer acquired Seagen for $43 billion in March 2023, the deal closed at a 33% premium to the prior 30-day VWAP; when Merck bought Prometheus for $10.8 billion in April 2023, the premium was 75%. Viking's market capitalization has oscillated between $2.8 billion and $3.4 billion through April 2026, implying a takeout range of $4.5–6.0 billion at comparable premiums. Sector cash positions remain elevated: ImmunityBio reported $380.9 million in cash and marketable securities for Q1 2026 alongside 168% year-over-year revenue growth, illustrating the broader balance-sheet capacity across mid-cap oncology and metabolic peers that would compete for the same M&A dollars. [BioSpace, May 8]

The near-term catalyst calendar tilts the question of whether Viking Therapeutics will be acquired toward Phase 3 readouts. VANQUISH-1 and VANQUISH-2, the company's pivotal obesity trials, began enrolling in Q2 2025 with initial data expected in late 2026 — a window that incentivizes pre-readout bids before pricing power inflates. Competing readouts from Exelixis, which reported Q1 2026 revenues of $610.8 million and a December 3, 2026 PDUFA date for zanzalintinib, demonstrate that the regulatory calendar is dictating deal timing across the sector. With the Federal Reserve holding the policy rate at 4.25–4.50% through the May FOMC meeting, financing costs remain a constraint, though strategic acquirers with cash on hand face minimal yield-curve headwinds in closing a deal before year-end. [BioSpace, May 6]

Traded on Polymarket — $1.7M Volume

Active market on Polymarket with $1.7M in total volume. Sufficient liquidity for most position sizes. Currently priced at 58c YES.